<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466504</url>
  </required_header>
  <id_info>
    <org_study_id>D11004</org_study_id>
    <nct_id>NCT01466504</nct_id>
  </id_info>
  <brief_title>Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin</brief_title>
  <official_title>A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skin toxicity is a frequently observed side effect in the era of &quot;molecularly targeted&#xD;
      therapies&quot;. Skin toxicity following administration of protein kinase inhibitors such as&#xD;
      sorafenib, regorafenib, lapatinib, sunitinib, and others can be debilitating to the patient,&#xD;
      resulting in dose reduction and discontinuation of treatment. The mechanisms of skin toxicity&#xD;
      induced by targeted chemotherapy, such as sorafenib or regorafenib, are poorly understood.&#xD;
      Further research is warranted to better understand the pathophysiology of drug-related skin&#xD;
      toxicity in this setting and develop correction strategies. This study tests the hypothesis&#xD;
      that sorafenib and regorafenib interfere with p63 expression and keratinocyte differentiation&#xD;
      and skin remodeling.&#xD;
&#xD;
      Eligible study participants will be evaluated clinically for evidence of skin toxicity during&#xD;
      their visits to the outpatient Oncology clinics. Study participants will undergo skin&#xD;
      biopsies before sorafenib or regorafenib treatment is initiated and once rash develops or 12&#xD;
      weeks into treatment with sorafenib or regorafenib. Skin biopsies will be performed in&#xD;
      Oncology clinics by the study investigators and clinic support staff.&#xD;
&#xD;
      Study participants will undergo both skin biopsies regardless of whether they develop a rash.&#xD;
      In patients who develop a rash the most representative lesion will be biopsied. A normal&#xD;
      appearing area of skin will be biopsied in participants who do not develop a rash.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual did not meet expectations. Over nearly 2 years just 4 subjects were treated on study.&#xD;
    The goal of 30 subjects was not attainable.&#xD;
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>p63 expression levels</measure>
    <time_frame>Week 12</time_frame>
    <description>Tissue collection is done within 7 days prior to treatment and when rash develops. If no rash develops, normal skin will be biopsied at week twelve of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Week 12</time_frame>
    <description>Sorafenib and regorafenib potentially interfere with p63 expression and keratinocyte differentiation and skin remodeling. The extent of interference may indicate extent of tumor response.</description>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>skin punch biopsy</intervention_name>
    <description>Skin biopsy prior to sorafenib or regorafenib treatment and when rash appears or 12 weeks into treatment.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      skin biopsies will be performed using a 4mm biopsy punch. Participants will undero 2 skin&#xD;
      biopsies - one prior to starting sorafenib or regorafenib, the other once rash develops. If a&#xD;
      rash does not develop within 84 days a biopsy of normal skin will be done.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer diagnosis of Renal Cell Carcinoma (RCC) or Hepatocellular Carcinoma (HCC) or&#xD;
        Colorectal Carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18 years old or older.&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of a solid tumor (RCC, HCC, or&#xD;
             colorectal cancer).&#xD;
&#xD;
          3. Participants are planning to initiate treatment with either sorafenib or regorafenib&#xD;
             as a single chemotherapeutic agent&#xD;
&#xD;
          4. Able to swallow and retain oral medication and does not have any clinically relevant,&#xD;
             active gastrointestinal disease or other condition that may significantly alter&#xD;
             absorption, distribution, metabolism, or excretion of drugs.&#xD;
&#xD;
          5. Be able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients who are or will be receiving other chemotherapeutic or molecularly targeted&#xD;
             agents in addition to sorafenib or regorafenib&#xD;
&#xD;
          2. Concurrent moderate or severe chronic inflammatory skin condition (eczema, psoriasis)&#xD;
&#xD;
          3. Concurrent blistering skin disorder of any severity (such as pemphigus, bullous&#xD;
             pemphigoid)&#xD;
&#xD;
          4. Connective tissue disorders with skin involvement (systemic lupus erythematosus,&#xD;
             scleroderma, dermatomyositis, etc.)&#xD;
&#xD;
          5. Patients manifesting an allergic skin reaction (such as urticaria) or skin reaction as&#xD;
             a complication of prior chemotherapy&#xD;
&#xD;
          6. Patients with skin lesions of infectious or non-infectious cause, precluding skin&#xD;
             biopsy&#xD;
&#xD;
          7. Patients not willing to undergo skin biopsy&#xD;
&#xD;
          8. Patients who are pregnant or planning to become pregnant during their participation in&#xD;
             the study.&#xD;
&#xD;
          9. Chemotherapy, targeted therapy, or biological therapy within two weeks of start of&#xD;
             treatment.&#xD;
&#xD;
         10. Ability to give informed consent is compromised by cognitive and/or decisional&#xD;
             impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexey V Danilov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White River Junction VA Medical Center</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.dartmouth.edu</url>
    <description>Norris Cotton Cancer Center</description>
  </link>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2011</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P63</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Regorafenib</keyword>
  <keyword>rash</keyword>
  <keyword>skin toxicity</keyword>
  <keyword>RCC</keyword>
  <keyword>HCC</keyword>
  <keyword>colorectal carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

